Total body irradiation and cyclophosphamide is a conditioning regimen for unrelated bone marrow transplantation in a patient with chronic myelogenous leukemia and renal failure on hemodialysis

被引:13
作者
Bischoff, ME
Blau, W
Wagner, T
Wagenmann, W
Dörner, O
Basara, N
Fauser, AA
机构
[1] Dept Hematol Oncol & Bone Marrow Transplantat, D-55743 Idar Oberstein, Germany
[2] Univ Lubeck, Dept Internal Med, Div Hematol Oncol, D-2400 Lubeck, Germany
[3] Univ Mainz, Sch Med, Hosp Idar Oberstein, Dept Radiol, D-6500 Mainz, Germany
[4] Univ Mainz, Sch Med, Hosp Idar Oberstein, Dept Internal Med, D-6500 Mainz, Germany
关键词
bone marrow transplantation; renal failure; cyclophosphamide; total body irradiation; pharmacokinetics; hemodialysis;
D O I
10.1038/sj.bmt.1701380
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Five years after the diagnosis of Ph chromosome-positive chronic myeloid leukemia (CML) a 31-year-old patient developed malignant nephrosclerosis with renal failure. He then underwent an allogeneic unrelated BMT in first chronic phase CML. The preparative regimen consisted of fractionated total body irradiation (TBI) and cyclophosphamide (CY), We studied the pharmacokinetics of cyclophosphamide on hemodialysis and compared clinical parameters including time to engraftment and toxicity with parameters of a patient with normal renal function who also received an unrelated marrow as treatment for CML in first chronic phase. Our results suggest that TBI/CY is a suitable conditioning regimen for allogeneic transplantation in patients with hematological malignancy and renal failure on hemodialysis.
引用
收藏
页码:591 / 593
页数:3
相关论文
共 16 条
  • [1] BAGLEY CM, 1973, CANCER RES, V33, P226
  • [2] REGIMEN-RELATED TOXICITY IN PATIENTS UNDERGOING BONE-MARROW TRANSPLANTATION
    BEARMAN, SI
    APPELBAUM, FR
    BUCKNER, CD
    PETERSEN, FB
    FISHER, LD
    CLIFT, RA
    THOMAS, ED
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (10) : 1562 - 1568
  • [3] European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia. Impact of HLA class II matching
    Devergie, A
    Apperley, JF
    Labopin, M
    Madrigal, A
    Jacobsen, N
    Carreras, E
    Prentice, HG
    Jouet, JP
    Kolb, HJ
    Herstenstein, B
    Bacigalupo, A
    Evensen, SA
    Ljungman, P
    deWitte, T
    Reiffers, J
    Nagler, A
    Clark, RE
    Goldman, JM
    Gratwohl, A
    [J]. BONE MARROW TRANSPLANTATION, 1997, 20 (01) : 11 - 19
  • [4] FRAPPAZ D, 1988, PRESSE MED, V17, P1209
  • [5] FUGER K, 1990, ONKOLOGIE, V13, P289
  • [6] GRAHAM MI, 1983, CANCER CHEMOTH PHARM, V10, P192
  • [7] HEINZEL G, 1982, PHARMACOKINETICS DRU, P207
  • [8] Peripheral blood stem cell transplantation in a multiple myeloma patient with end-stage renal failure
    Rebibou, JM
    Caillot, D
    Casasnovas, RO
    Tanter, Y
    Maillard, N
    Solary, E
    Rifle, G
    Guy, H
    [J]. BONE MARROW TRANSPLANTATION, 1997, 20 (01) : 63 - 65
  • [9] PHARMACOKINETICS AND METABOLISM OF CYCLOPHOSPHAMIDE ADMINISTERED AFTER TOTAL-BODY IRRADIATION OF BONE-MARROW TRANSPLANT RECIPIENTS
    SCHULER, U
    WAIDELICH, P
    KOLB, H
    WAGNER, T
    EHNINGER, G
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 40 (05) : 521 - 523
  • [10] REPEATED HIGH-DOSE CYCLOPHOSPHAMIDE ADMINISTRATION IN BONE-MARROW TRANSPLANTATION - EXPOSURE TO ACTIVATED METABOLITES
    SCHULER, U
    EHNINGER, G
    WAGNER, T
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1987, 20 (03) : 248 - 252